Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
FDA Rejection Pushes Incyte Stock Sharply Lower
11:05am, Friday, 24'th Mar 2023
The shares of Incyte Corporation ( NASDAQ:INCY) are down 5.3% at $68.33 at last check, after the U.S. Food and Drug Administration (FDA) failed to approve the extended-release version of the compan
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
09:17am, Friday, 24'th Mar 2023
Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi. The post Incyte Stock Dives On Surprise Rejection For Updated Jakafi appear
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
08:26am, Friday, 24'th Mar 2023
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
01:44pm, Thursday, 23'rd Mar 2023
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
04:13pm, Tuesday, 21'st Mar 2023
Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
12:59pm, Monday, 20'th Mar 2023
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
11:17am, Tuesday, 07'th Mar 2023
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendati
10 S&P 500 Stocks Are Practically Immune To More Fed Rate Hikes
08:00am, Monday, 06'th Mar 2023
Is the Fed done jacking up interest rates or not? Angst over that question is torturing the stock market — but a handful of S&P 500 stocks aren't worried.
Incyte (INCY) Reports Positive Long-Term Data From HS Study
01:33pm, Monday, 13'th Feb 2023
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Markets Rise on Powell's Inflation Comments
05:50pm, Tuesday, 07'th Feb 2023
U.S. equities posted gains on Feb. 7 after Fed Chair Jerome Powell said that inflation was easing but noted that rate hikes would continue if needed.
Incyte Corporation (INCY) Q4 2022 Earnings Call Transcript
12:11pm, Tuesday, 07'th Feb 2023
Incyte Corporation (NASDAQ:INCY ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
12:03pm, Tuesday, 07'th Feb 2023
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
10:05am, Tuesday, 07'th Feb 2023
Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics leapt on its own beat-and-raise. The post Incyte, Haemonetics Post Earnings Beats; One Surges Wi
Incyte (INCY) Tops Q4 Earnings and Revenue Estimates
09:47am, Tuesday, 07'th Feb 2023
Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Incyte (INCY)
02:18pm, Wednesday, 01'st Feb 2023
Incyte (INCY) could produce exceptional returns because of its solid growth attributes.
